H.C. Wainwright raised the firm’s price target on Atossa Therapeutics to $6 from $4 and keeps a Buy rating on the shares following the Q1 report. The analyst cites lower operating expenses for the target increase. The firm expects Z-endoxifen 24-week treatment period data from the I-SPY 2 study for neoadjuvant breast cancer in the second half of 2024.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATOS:
- Atossa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
- Atossa Therapeutics announce support of new breast cancer screening guidelines
- Atossa Therapeutics Announces Support of New Breast Cancer Screening Guidelines
- Atossa Therapeutics Announces Expanded Research Agreement with Weill Cornell Medicine to Further Evaluate Synergy Between Antibody Drug Conjugates (ADCs) and (Z)-Endoxifen
- Atossa announces expanded research agreement with Weill Cornell Medicine
